David Neff is a co-founder of the recently formed Applied Genomics and Bioinformatics Workgroup. He is also currently a consultant for the Michigan Department of Health and Human Services. He recently retired from Merck as the US Medical Affairs Strategy Leader for Cardiovascular Franchises. He chaired the US Medical Affairs Teams and US Advisory Boards for Lipids and Thrombosis. He helped bring ezetimibe, vorapaxar, sitaglyptin, losartan and other agents to market during his 14 year tenure at Merck. He coordinated research activities between external and internal researchers for clinical trials and investigator initiated studies. He was academic liaison for 65 medical schools. He was also involved in health policy, medical informatics, medical education, managed care, and quality improvement initiatives. He has authored several papers related to lipid metabolism and thrombosis. Prior to joining Merck, one of several roles included being the Director of Pharmaceutical Studies in the Office of Research at Michigan State University.
Dr. Neff attended Michigan State University in East Lansing, Michigan, where he graduated with a Bachelor of Science degree in physiology in 1976. Additional post graduate studies included biochemistry, neuroscience & systems science. He graduated from the Michigan State University College of Osteopathic Medicine (MSUCOM) in 1980. He is board certified in Family Medicine. He remains on the clinical faculty at MSUCOM in the Department of Family and Community Medicine. He is a member of the American Heart Association (AHA), the American Diabetes Association (ADA), the National Lipid Association (NLA), the American Society for Quality (ASQ), and the American Osteopathic Association (AOA). He is on the Board of Directors for the Midwest Lipid Association, an affiliate of the National Lipid Association.